Efficacy of bimolane in the Malassezia ovalis model of psoriasis.
Bimolane, an analog of razoxane has been used in China with comparable efficacy but less toxicity than razoxane in the treatment of psoriasis. In an attempt to characterize further its mode of action it was administered both systemically and topically in the Malassezia ovalis animal model of psoriasis. Intravenous methotrexate and topical 0.1% betamethasone valerate were also used as positive control treatments. The animal model of psoriasis was effectively treated by bimolane, both systemically and topically, and also by parenteral methotrexate and topical betamethasone valerate. The time course of bimolane's effect with this model was different from methotrexate's suggesting the possibility of a different mode of action. Because bimolane, like razoxane, is an ethylene diamino tetraacetate acid (EDTA) derivative, it is possible that its effects on this reaction relate to its chelating properties and that inhibition of complement activation is important to its mode of action.
Xu
B
B
Department of Pharmacology, Shanghai Institute of Materia Medica, Academia Sinica, China.
Noah
P W
PW
Skinner
R B
RB
Bale
G
G
Chesney
T M
TM
Rosenberg
E W
EW
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D001624:Betamethasone Valerate / Q000008:administration & dosage; D004195:Disease Models, Animal; D005260:Female; D007275:Injections, Intravenous; D008290:Malassezia; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits; D011929:Razoxane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology
C031186:bimolane; D011929:Razoxane; D001624:Betamethasone Valerate; D008727:Methotrexate